Intravenous immunoglobulins in neonates and infants: an overview. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Intravenous immunoglobulins in neonates and infants: an overview.

Pediatr Infect Dis. 1986 May-Jun;5(3 Suppl):S217-9. Unique Identifier : AIDSLINE MED/86232768
Stiehm ER

Abstract: These reports indicate that we have just begun to tap the potential uses of IGIV in the prevention and therapy of pediatric disease. The ability to give large amounts of immunoglobulin intravenously repeatedly and in a safe fashion allows us to achieve and maintain very high levels of antibody. These high antibody levels can prevent infection in high risk individuals (e.g. the premature, the immunocompromised, the exposed susceptible), can treat a number of bacterial and viral infections heretofore considered refractory to antibody therapy and can achieve immunomodulating effects not necessarily related to specific antibody titers; these effects can be used therapeutically in disorders associated with aberrant immune responses (Kawasaki disease, idiopathic thrombocytopenia purpura, etc). We are particularly grateful to all of the participants who traveled so far to participate in this conference; to Sandoz Laboratories, who sponsored and arranged the symposium; and to the weather person, who brought us a spectacular view of the Jungfrau.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/THERAPY Antibody Formation Antigens, Bacterial/IMMUNOLOGY Bacterial Infections/IMMUNOLOGY/*THERAPY Human Immunization, Passive Immunoglobulins/*ADMINISTRATION & DOSAGE Infant Infant, Newborn Infant, Newborn, Diseases/*THERAPY Infant, Premature Injections, Intravenous Paramyxovirus Infections/THERAPY Polysaccharides, Bacterial/IMMUNOLOGY Respiratory Syncytial Viruses Streptococcal Infections/IMMUNOLOGY/THERAPY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/immunology/therapyantibodyformationantigens,bacterial/immunologybacterialinfections/immunology/KWDtherapyhumanimmunization,passiveimmunoglobulins/KWDadministration&dosageinfantinfant,newborninfant,newborn,diseases/KWDtherapyinfant,prematureinjections,intravenousparamyxovirusinfections/therapypolysaccharides,bacterial/immunologyrespiratorysyncytialvirusesstreptococcalinfections/immunology/therapyjournalarticle
860930
M8690196

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .